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The prevalence of diabetes continues to increase world-wide and is a leading cause of morbidity, mortality, and
rapidly rising health care costs. Although strict glucose control combined with good pharmacological and
non-pharmacologic interventions can increase diabetic patient life span, the frequency and mortality of myocardial
ischemia and infarction remain drastically increased in diabetic patients. Therefore, more effective therapeutic
approaches are urgently needed. Over the past 15 years, cellular repair of the injured adult heart has become the
focus of a rapidly expanding broad spectrum of pre-clinical and clinical research. Recent clinical trials have achieved
favorable initial endpoints with improvements in cardiac function and clinical symptoms following cellular therapy.
Due to the increased risk of cardiac disease, cardiac regeneration may be one strategy to treat patients with diabetic
cardiomyopathy and/or myocardial infarction. However, pre-clinical studies suggest that the diabetic myocardium
may not be a favorable environment for the transplantation and survival of stem cells due to altered kinetics in
cellular homing, survival, and in situ remodeling. Therefore, unique conditions in the diabetic myocardium will
require novel solutions in order to increase the efficiency of cellular repair following ischemia and/or infarction.
This review briefly summarizes some of the recent advances in cardiac regeneration in non-diabetic conditions and
then provides an overview of some of the issues related to diabetes that must be addressed in the coming years.
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Diabetes mellitus (DM) is a world-wide epidemic for
children and adults in many countries with expanding
negative impacts on health and many diseases [1].
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in patients with diabetes,
accounting for an estimated 80% of all diabetic deaths
in North America [1]. About 75% of mortality in diabetic
patients is attributed to CVDs, leading to myocardial
infarction (MI) and heart failure while acute MI results in
massive necrosis of the myocardium and myocyte cell loss
[2]. In the heart, diabetes enhances fatty acid metabolism,
suppresses glucose oxidation, and modifies intracellular
signaling, leading to impairment in multiple steps of
excitation-contraction coupling, inefficient energy produc-
tion, and increased susceptibility to ischemia/reperfusion
injury. Damage and loss of the normal microvasculature
and adverse cardiac remodeling of the extracellular matrix
also result in contractile dysfunction in diabetic hearts [3].* Correspondence: lu.cai@louisville.edu
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reproduction in any medium, provided the orFinally, ischemia and infarction result in irreversible
cardiomyocyte loss followed by fibrosis in the affected
regions [3,4].
Myocardial hypertrophy is the major adaptive mechanism
to meet increased physiologic demand caused following
myocardial injury in higher vertebrates while cardiomyocyte
proliferation and myocardial regeneration can occur in
lower vertebrates. In contrast to this traditional paradigm,
recent advances in stem cell biology suggest that the adult
mammalian heart has a limited capacity to regenerate
functional cardiomyocytes (CM) following cardiac injury
[5-7]. Identification of cardiac stem cells (CSCs) in the
heart has accelerated research in the new field of cardiac
regeneration [5-7]. Preclinical and clinical studies have
implanted a variety of multipotent stem cells (SCs) into
infarcted hearts and have shown variable results in
the ability of these implanted cells to survive and to
differentiate into cardiac lineages [5-8]. Many studies
have also explored the use of non-cellular adjuvant
therapies to either stimulate myocardial recovery or to
facilitate the delivery, survival, and integration of implanted
cells [9,10]. The filed is far from reaching a consensus
on the optimal approach and therefore the field ofl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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novel methods to deliver biomaterials and cells into the
damaged myocardium with the goal of tissue remodeling
and recovery.
Concurrent with experiments to repair the non-diabetic
heart, several efforts have explored the unique challenges
of effected cellular transplantation and regeneration in the
diabetic myocardium with diverse results [11-14]. The
current status of cardiac regeneration and the potential
application of SCs in the field of cardiac damage and
recovery are briefly reviewed, followed by a summary
of the limited information available regarding the
preclinical and clinical use of SCs to repair the diabetic
myocardium. As would be expected, substantial work
is required to develop and refine optimal methods
for cardiac repair and regeneration of the damaged
diabetic heart.
Cardiac regeneration: from animal studies to human cases
Cardiac SCs
The fact that heart maintains its regenerative capacity
was first reported at the early 1980s for the repair of the
injured atrium [15,16]. But it was until 2000s for the first
report that there are cycling ventricular myocytes in the
normal and pathologic adult heart, including human
hearts [5-7]. Several investigators have found that
these regenerative cells, named CSCs, have very low
or minimal regenerative activity under physiological
condition, but have a great potential to generate new
CM after MI [17]. Subsequent studies have shown that
CSCs are multipotent and can differentiate into multiple
cardiomyocyte lineages as well as smooth muscle and
endothelial cells [5,18]. Although c-kit and/or Sca-positive
(c-kit+ and/or Sca+) cells are capable of differentiating
into functional CM, the population and differentiation
potential of these two subpopulations of CSCs differ
dramatically [5]. Preclinical studies have shown that
resident c-kit+ CSCs can be isolated from the adult
heart, expanded in vitro, and then injected into the
damaged adult heart to stimulate cardiac repair after
infarction [5].
The recent SCIPIO (Stem Cell Infusion in Patients
with Ischemic Cardiomyopathy) clinical trial confirmed
the feasibility of using autologous CSCs as a regenerative
approach for the injured adult human heart [8]. In this
clinical trial, patients who had remote MI were recruited
at the time of coronary artery bypass graft surgery
to subsequently received intracoronary autologous
cells derived from c-kit+ CSCs. Cell-treated patients
demonstrated significant improvements in symptoms,
quality of life, and left ventricular (LV) ejection fraction at
4 months’ follow-up. Cardiac magnetic resonance showed
a significant reduction in myocardial scar mass from
baseline at 4 months and 12 months [8].Bone marrow SCs
Although CSCs may have efficacy, it has been estimated
that there is only 1 c-kit+ cell per 10,000 CM in adult
mammalian myocardium [19], consistent with their
primary roles in local cellular homeostasis and making
the isolation and expansion of sufficient CSCs for clinical
therapies extremely challenging. In contrast, bone marrow
(BM) derived stem cells (BMCs) or mesenchymal stem
cells (MSCs) from the circulating blood have been
used successfully to treat hematologic diseases for
over 60 years. As mesodermally derived cells, MSCs
have been investigated for their capacity to generate
CM with the goal of generating cells for cardiac repair and
regeneration as an alternative to the use of skeletal muscle
derived cells due to the failure of myoblast cells to
survive following transplantation or to produce clinical
improvement [20,21]. While the efficiency of generating
functional CM from MSCs in vitro is low, their efficiency
in some laboratories has been reported to be comparable
to the generation of CM from other stem cells sources.
Therefore, numerous groups explored the feasibility of
directly using BMCs [22] or inducing the mobilization of
BMCs into the circulation for cardiac repair [23]. There is
evidence that BMCs contribute to both angiogenesis and
the preservation of injured myocardium (and perhaps
the formation of new working myocardium) [24-26].
Following a geometric expansion of small and large
clinical trials to assess the efficacy of using BMCs in
patients following myocardial infarction or with ischemic
cardiomyopathy there have been a number of meta-analyses
of the studies completed using randomized controlled
trial (RCT) approaches. A Cochrane review of the use
of SCs for the treatment of acute MI identified 33
RCTs including 1765 participants to compare the use
of autologous stem/progenitor cells with no cells [27].
There was substantial heterogeneity noted in the methods
between the trials. While there was evidence for improved
left ventricular ejection fraction and reduced left ventricular
volumes following stem cell therapy there was no statisti-
cally significant reduction in morbidity or mortality [27]. A
meta-analysis of clinical trials using BMCs in ischemic
cardiomyopathy patients revealed 10 RCTs containing 519
patients of 226 reported trials [28]. This analysis also
noted a sustained improvement in LV ejection fraction at
12 months with evidence that intramyocardial injection
was beneficial versus intracoronary infusion. However,
overall the improvements were modest and no reduction
in morbidity or mortality was noted [28].
A variety of adjuvant approaches have been investigated
to increase the capacity of BMCs and MSCs to generate
functional CM. A very early study showed that when
mouse BMC were incubated in medium conditioned by
marrow fibroblasts, the survival of pluripotent stem cells
(PSCs), measured by colony forming units (CFUs), was
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in fresh medium. Medium conditioned by fibroblasts
from other adult tissues–spleen, bone, and subcutaneous
tissue–did not increase CFUs survival, but medium
conditioned by embryo BM did. The increase in CFUs
survival by BMC in fibroblast-conditioned medium was
not accompanied by any change in the total number of
nucleated cells of the incubated marrow nor by any
comparable increase in the survival of granulopoietic
SCs or erythropoietic SCs [29]. These results indicate
that marrow fibroblasts produce factors that increase
the survival of CFUs, which provides some cues for
the maturation of both embryonic and somatic SCs.
Inducible pluripotent SCs
Although CSC therapies are under investigation as
allogeneic or autologous strategies for myocardial repair,
the lack of sources for human CM has limited the feasibility
of this approach. By overexpressing the transcription
factors, Oct4, Sox2, Klf4, and c-Myc in adult human
fibroblasts, Takahashi and Yamanaka successfully generated
human iPSCs with the capacity to expand and differentiate
into all mammalian cell lineages, similar to embryonic
stem cells (ESCs) [30]. This significant turning point in
nuclear reprogramming research has vast implications for
the generation of autologous, patient-specific PSCs for
research and therapeutic purposes and resulted in the 2012
Nobel Prize for Medicine. This is particularly important for
the generation of cardiomyocytes for cardiac repair as
to date there are no somatic sources for cells that can
generate mature cardiomyocytes with high efficiency.
The initial focus with iPSCs has been to generate,
characterize, and mature iPSC-CM using a variety of
in vitro conditioning protocols [31-33]. These protocols
begin with iPSCs generated that use the traditional
retroviral vectors to introduce reprogramming factors;
however, these cells have also been noted to retain a
small risk for tumor formation despite differentiation
towards a cardiac lineage [34]. Alternate strategies
include the use of non-integrating episomal vectors that
introduce the same factors without introducing viral
sequences into the reprogrammed cells [35,36] or the
use of alternate reprogramming strategies to directly
generate cardiomyocyte lineages from somatic fibro-
blasts without entering a fully pluripotent state [36-39].
Following CM lineage induction from iPSC, there are
various in vitro and vivo conditioning strategies along
with various delivery methods that involve the injection
or implantation of cells, gels, and tissues [40-45]. Each
of these methods has advantages and disadvantages
that result in cardiomyocytes with varying degrees of
functional maturity and the reader is directed to several
recent reviews that discuss these issues in greater detail
[43,46,47]. Following transplantation of iPSC-CM intopreviously infarcted myocardium, newly differentiated
cardiac myocytes and formation of gap junction proteins
can be identified as early as 2 weeks post-MI [46], and
transplanted iPSCs significantly inhibited apoptosis and
fibrosis and improved cardiac function [40], suggesting that
these newly formed cardiac myocytes were integrated into
the native myocardium. The combined transplantation of
iPSC-CM and vascular cells derived from human iPSCs
into the border zone of Yorkshire pig MI reduces
regional wall stress, stimulates neovascularization, and
improves border zone perfusion, which in turn results
in marked increases in border zone contractile func-
tion and ATP turnover rate [41]. There will certainly
continue to be exciting developments as this field
rapidly evolves [48,49].
SDF-1/CXCR system
There is clear evidence that one mechanism active in
myocardial recovery from injury is the homing of
mesenchymal stem cells to damaged myocardium.
Stromal derived factor-1 (SDF-1) is a CXC chemokine that
was first identified as a pre-B-cell stimulating factor
expressed by BM stromal cells. SDF-1 specifically interacts
with its receptors, CXCR4 and/or CXCR7, and induces
migration of monocytes, lymphocytes, and endothelial
cells [50-52]. When tissues are damage the expression of
SDF-1 in damaged tissues are up-regulated to homing
BMCs into damaged tissues for the repair and recovery
with subsequent neo-angiogenesis [50-52].
Regarding the role of SDF-1 in cardiac regeneration,
SDF-1 expression increases in the heart immediately
after MI and is downregulated within 7 days in the Lewis
rat coronary artery ligation model [40]. Eight weeks after
MI, transplantation of fibroblasts stably transfected to
express SDF-1 and increase the homing of CD117+
(also called c-kit+) MSCs into the peri-infarct zone of
syngeneic rat hearts resulted in greater LV mass and
better cardiac function, suggesting the important role
of SDF-1 to induce MSCs homing to injured myocardium
[53]. Later, in mice subjected to ischemic preconditioning,
myocardial SDF-1α mRNA was also increased 3 hours
later. Myocardial SDF-1α and CXCR4 mRNA and protein
were found to be expressed in both cardiac myocytes
and fibroblasts. In vivo, administration of SDF-1α
before 30 minutes of coronary occlusion followed by
4 hours of reperfusion decreased infarct size. The
decrease in infarct size with SDF-1α administration
was blocked by CXCR4 specific blocker AMD3100,
supporting that SDF-1α and its receptor, CXCR4,
confers protection against ischemia/ reperfusion dam-
age [54]. These findings stimulated the further studies
for the role of SDF-1α or β in the regulation of
inflammatory responses during myocardial repair and
regeneration [55-57].
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regeneration
Due to the high prevalence of heart disease in adults
with diabetes, therapeutic approaches for SC-mediated
cardiac repair have been studied in pre-clinical diabetic
models and in a limited number of diabetic patients.
Cardiac magnetic resonance in diabetic adults reveals
that the overall prevalence of myocardial scar was 4.3%
in patients with elevated mean glycosylated hemoglobin
and macroalbuminuria [58]. These diabetic patients are
assumed to be potential candidates for the use of SCs to
improved cardiac function [11-14] though this patient
population may not respond as effectively due the altered
biology of the diabetic heart.
MSCs have been infused systemically into diabetic rats
with cardiomyopathy to explore the effect on heart rate,
LV developed pressure, and contractility index in the
diabetic rats induced by streptozotocin (STZ) [12]. In
this study, MSCs were derived from the BM of male
albino rats with the characteristics of CD29 expression
and then were infused into female STZ-induced diabetic
rats. Diabetic rats which systemically received MSCs by
subcutaneous infusion at six weeks of age showed
significantly lower serum glucose and increased serum
insulin levels compared with the control (untreated)
diabetic group. MSC administration also significantly
improved cardiac function in MSC-treated diabetic
rats. Of note, the sry gene was detected by PCR in
the pancreatic and cardiac tissues of the MSC-treated
diabetic rats. Rat BM harbors cells that have the capacity
to differentiate into functional insulin-producing cells
capable of controlling blood glucose level in diabetic
rats [12]. A similar study was also reported by Zhang et al.
(2008), in which STZ-induced female diabetic rat (8 weeks
after diabetic induction) were dosed with exogenous MSCs
via femoral vein infusion. At 4 weeks after transplantation
MSCs were found to present in the myocardium and a
small percentage of the transplanted MSCs expressed the
cardiac markers Troponin T and myosin heavy chain.
MSCs transplantation significantly increased myocardial
arteriolar density and decreased the collagen volume in
diabetic myocardium. Furthermore, MSCs transplantation
increased matrix metalloproteinase-2 (MMP-2) activity
and decreased transcriptional level of MMP-9. These
results show that MSCs transplantation improved
cardiac function in diabetic rat model, possibly through
angiogenesis and attenuation of cardiac remodeling [14].
However, due to systemic infusion of MSCs the cardiac
function improvement may be partially explained by the
pancreatic β-cell regeneration for these two studies as they
also observed the pancreatic β-cell regeneration [12].
Several studies may provide evidence that SCs can dir-
ectly improve cardiac damage and function in the diabetic
heart. Li et al. explored whether anoxic pre-conditioned(AP) MSCs can improve diabetic myocardium [13]. Four
months after the onset of diabetes, diabetic rats were
randomly given an intramyocardial injection of MSC with
and without AP. Two weeks after transplantation, MSC,
especially AP-MSC greatly increased the fractional
shortening of the diabetic heart. AP-MSC intramyocardial
injection also increased the capillary density of diabetic
myocardium, attenuated myocardial fibrosis by increasing
the activity of MMP-2 and inhibiting TGF-β, and reduced
cardiac apoptotic cell death, possibly mediated through
cardiac upregulation of Bcl-2/Bax ratio and inhibiting
the expression and activation of caspase-3 [13]. This
study supported the possible role for intramyocardial
transplantation of MSCs in the regeneration of diabetic
hearts and also indicated the potential enhancement of
this effect by AP.
Wang et al. [59] also investigated the possibility for
transplantation of MSCs to recover and improve cardiac
nerve sprouting and increase the ratio of parasympathetic
to sympathetic nerve fibers under diabetic condition.
Diabetic rats (STZ) were placed in the groups with and
without MSC treatment via direct myocardial injection
at 4 months after the onset of diabetes. At 2 weeks after
MSC treatment, the density of choline acetyltransferase
(a marker for parasympathetic nerves) and tyrosine
hydroxylase positive nerve fibers (a marker for sympathetic
nerves) in MSC-treated group was higher in MSC treated
hearts than in diabetic controls. The staining ratio of
choline acetyltransferase to tyrosine hydroxylase in MSC
group was higher than in diabetic control. The inducibility
of ventricular arrhythmias in the MSC-treated diabetic
group was lower than in the DM control [59]. This study
suggests that MSC therapy significantly promoted cardiac
nerve sprouting and increase the ratio of parasympathetic
to sympathetic nerve fibers, which may also suppress the
inducibility of ventricular arrhythmias in the diabetic rats.
Given the low rates of implanted cell survival and differ-
entiation into mature CM phenotypes, it is important to
determine the impact of the diabetic micro-environment
on MSC and iPSC implantation, survival, and maturation.
Following transplantation into infarcted non-diabetic mice,
iPSCs generated from H9c2 cells can inhibit apoptosis and
differentiate into cardiac myocytes, Yan et al. recently have
examined whether transplanted iPSCs in the infarcted
diabetic db/db and non-diabetic mice can differentiate into
vascular smooth muscle (VSM) and endothelial cells (ECs)
as well as activate endogenous c-kit+ cells to enhance
neovascularization along with improved cardiac function.
About 50,000 iPSCs were transplanted intramyocardially
into the peri-infarct zone of infarcted db/db and C57BL/6
mice. Post-treatment there was a significant increase in
VSM and ECs in the infarcted hearts following iPSC
transplantation compared with MI and sham groups in
both db/db and C57BL/6 animals. Furthermore, the
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increase in c-kit+ activated VSM and ECs confirmed with
combined stains of c-kit+ and cell specific markers,
compared with respective controls. Histology data in
the MI + iPSC group also established a significant increase
in coronary artery vessels compared with MI, indicating
neovascularization. Furthermore, their data demonstrated
significantly improved cardiac function following iPSC
transplantation. Thus, the increased neovascularization
noted in the infarcted db/db and C57BL/6 mice is
associated with improved cardiac function following
iPSC transplantation [60]. This study was also supported
by the most recent study where iPSC, derived from H9c2
cells, were transplanted into STZ-induced diabetic mice
and resulted in a significant improvement of diabetic
cardiac structure and function by preventing diabetes-
induced cardiac cell death, oxidative damage, remodeling,
and dysfunction [61].
Combined the above studies, MSC and iPSC therapies
appear to result in enhanced cardiomyocyte proliferation
as well and increased endothelial cell incorporation into
new vessels and even cardiac nerve sprouting and increase
the ratio of parasympathetic to sympathetic nerve fibers. All
of these events are important for the repair and recovery of
diabetes-induced cardiac cell loss and remodeling, which
seem no significant difference from the normal heart
and normal SCs discussed in the above section since
the SCs in the above studies were predominantly collected
from normal conditions [13,59-61].
In contrast to the above studies that used non-diabetic
cells, Govaert et al. reported that diabetic BM mononuclear
cells (MCs) were unable to improve cardiac function
post-MI, whereas healthy BM MCs were able to preserve
fractional shortening [9]. What they did is that collecting
BM MCs from type 2 diabetic male BKS.Cg-m+/+Lepr
(db)/J mice or control C57BLKS/J (non-diabetic control)
mice and then transplanted these diabetic or control BM
MCs into female BKS.Cg-m+/+Lepr(db)/J mice with
ischemic myocardium that was induced by left anterior
descending artery ligation. At week 5, cardiac func-
tion determined using echocardiography and invasive
hemodynamic measurements showed that diabetic BM
MCs were unable to improve cardiac function post-MI,
whereas control BM MCs were able to preserve fractional
shortening [11]. This study raises the critical issue that
diabetic BM MCs may be significantly impaired in
their ability to improve cardiac function after myocardial
infarction compared with control BM -MCs.
Possible negative impacts of diabetes on SCs and cardiac
regeneration
Impairment of diabetes on SCs
After Govaert et al. reported the impairment of diabetes on
BM MSC capacity to stimulate cardiac cell regeneration[11], Yan et al. also proclaimed that type 2 diabetes
inhibited the multipotency of MSCs and impaired
their capacity to increase blood flow recovery after the
induction of hind-limb ischemia [62]. This conclusion
was made based on the following observation. MSCs
from db/db or control mice were transplanted into
control recipients after induction of hind limb ische-
mia. Control recipients of db/db MSCs demonstrated
adipocyte infiltration of ischemic muscle and impaired
neovascularization; Control recipients of control MSCs
showed no intramuscular adipocyte infiltration and had
significantly enhanced neovascularization. Confocal
microscopy showed that the percentage of MSCs that
differentiated into an adipocyte phenotype was greater
and into an endothelial cell was less in control recipients
of db/db MSCs than those of control MSCs.
Diabetic impairment of MSCs has also been noted in
human MSCs [63]. For instance, sternal BM aspirates
were taken at the time of coronary artery bypass graft
surgery from patients either with coronary artery disease
(CAD) and diabetes (CAD-DM) or only CAD, from
which hMSCs were obtained. Rats with experimentally
induced CAD model were then treated with MSCs
from patients with CAD-DM or CAD by injection
into the infarcted myocardium. The in vitro growth
curves showed that proliferation of hMSCs in the
CAD-DM group was significantly lower than in the CAD
group. Transplantation of CAD hMSCs in the infarcted
border zone of rats with CAD could improve rat cardiac
function, examined at 4 weeks after transplantation,
but transplantation of CAD-DM hMSCs did not improve
cardiac function, suggesting the impairment of DM on
hMSCs [63].
Endothelial progenitor cells (EPCs) play a fundamental
role in tissue regeneration and vascular repair both by
differentiating into endothelial cells and by the secretion
of vasoactive substances that promote angiogenesis and
maintain vascular homeostasis in the myocardium and
vascular system. The deleterious effect of high glucose
on the EPC function was reported [64]. In this study,
whole BM was isolated from the femurs and tibias of
Sprague–Dawley rats. Through in vitro incubation with
different cytokines, the late EPCs were obtained to be
incubated with different concentrations of glucose for
24 hours. Secretion of nitric oxide, tissue plasminogen
activator, plasminogen activator inhibitor-1, prostaglandin
I2, and vascular endothelial growth factor were measured
as the secretary function of EPCs. High glucose treatment
significantly reduced the late EPC secretion function
[64]. The finding from the in vitro cultured late EPCs
of rats was in a line with the recent human study
[65]. Furthermore, hyperglycemia or diabetes not only
impairs BM SCs, but also impairs other SCs derived
from subcutaneous fat and omentum fat [66].
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environment
In fact, diabetes or hyperglycemia not only impairs
SCs as discussed above, but also impairs organ’s function
of diabetic individuals [67]. To test whether muscle
regeneration is impaired in ob/ob and db/db mice,
which are common mouse models of obesity and type
2 diabetes, a muscle injury was made by cardiotoxin
injection in ob/ob and db/db mice, in which muscle
regeneration was found to be delayed compared to
non-diabetic controls [67].
She et al. recently found that diabetes suppresses CSC
accumulation in the heart [68]. For this study, an MI
model was induced in non-diabetic and diabetic rats by
left coronary artery ligation. On Day 5 post-MI, the
accumulation of CSCs, by examining BrdU-labeled CSCs,
significantly increased in the peri-infarcted myocardium
in non-diabetic rats, which led to an improvement in
cardiac function 3 weeks after MI. However, the accumula-
tion of CSCs markedly decreased in diabetic rats, followed
by the decline of cardiac function. Stem cell factor (SCF)
expression, followed with phosphorylation of ERK1/2 and
p38 MAPK, were also significantly down-regulated in the
peri-infarcted myocardium in diabetic rats compared to
non-diabetic rats [68]. To see whether the down regulation
of ERK1/2 and p38 MAPK phosphorylation is related
to the impairment of cardiac homing CSCs, application
of either the MEK-specific inhibitor PD98059 or the
p38 MAPK-selective inhibitor SB203580 could completely
blocked SCF expression and the migration of CSCs.
This study suggests that hyperglycemia decreased SCF
expression via reduction in ERK1/2 and p38 MAPK
phosphorylation and further inhibited the migration
of CSCs [68].
Possible strategies to prevent or reverse the negative
diabetic effect on SCs and cardiac regenerative therapies
Improvement of stem cell function impaired by diabetes
The observation that hyperglycemic inhibition of the
migration of CSCs is due to the suppression of SCF
expression via reduction in ERK1/2 and p38 MAPK
phosphorylation may imply a possibility whether activation
of ERK1/2 and p38 MAPK can be a tool to prevent
diabetic suppression of myocardial SCF expression to
attract the migration of CSCs to infarcted cardiac tissues.
Yan et al. demonstrated that in vitro db/db MSCs
exhibited greater oxidant stress, greater adipocyte
differentiation, and less endothelial differentiation than
control MSCs, and these differences were reversed
by treatment with N-acetylcysteine or Nox4 siRNA
suggesting that Nox4-related oxidative stress in the
diabetic mice play critical role in impairing the function
of MSCs. Reversal of db/db MSC oxidant stress by in vivo
pretreatment with Nox4 siRNA before transplantationreversed their impaired capacity to augment post-ischemic
neovascularization. Therefore, Type 2 diabetes-induced
oxidant stress restricts the multipotency of MSCs and
impairs their capacity to increase blood flow recovery
after the induction of hind-limb ischemia. Reversal of
MSC oxidant stress might permit greater leverage of the
therapeutic potential of MSC transplantation in the setting
of diabetes [62].
Khan et al. also explored the improvement of SCs for
use in diabetic models by preconditioning diabetic MSCs
to increase their ability to repair the diabetic heart. For
this study diabetes was induced in C57BL/6 mice with
STZ for 5 consecutive days. MSCs isolated from diabetic
animals were preconditioned with medium from CM
exposed to hydrogen and high glucose (H/HG). Increased
Akt phosphorylation, proliferation, angiogenic ability, and
reduced levels of apoptosis were observed in diabetic
MSCs pre-conditioned with medium from H/HG-treated
CM compared with those from non-treated controls.
Diabetic-mouse-derived MSCs (dmMSCs) preconditioned
with medium from H/HG-treated CM were transplanted in
diabetic animals and demonstrated increased homing con-
comitant with augmented heart function and, in addition,
reduced fibrosis, apoptosis, and increased angiogenesis was
observed in diabetic hearts at 4 weeks after transplantation
of preconditioned dmMSCs compared with hearts with
non-treated diabetic MSCs. This study suggests that
preconditioning with the medium from H/HG-treated
CM enhances survival, proliferation, and the angiogenic
ability of dmMSCs, augmenting their ability to improve
function in a diabetic heart [69].
In vitro studies have indicated that exposure of high
glucose causes epigenetic changes of BM-derived MSCs
[70], and to understand which is important for the
developing strategies to intervene the epigenetic change
of these cells exposed to hyperglycemia. Zhu et al. used
a microRNA microarray approach to identify that
miRNA-32-5p expression is significantly reduced under
hyperglycemic conditions in rat BM-derived MSCs.
Expression of miRNA-32-5p targets the 3′-untranslated
region of the mRNA encoding phosphatase and tensin
homologs deleted on chromosome 10 (PTEN), a negative
regulator of the phosphatidylinositol 3-kinase (PI3K)/Akt
signaling pathway. Exposure to high glucose reduced
miR-32-5p expression, induced PTEN expression, and
inhibited activation of the PI3K/Akt signaling pathway of
MSCs. Conversely, overexpression of miR-32-5p inhibited
the expression of PTEN, ameliorated the inhibitory effect
of high glucose on the PI3K/Akt signaling pathway,
and promoted cell cycle progression from G0/G1 to
G2/M and S phases. This study indicates that exposure of
MSCs to hyperglycemic conditions reduces miR-32-5p
expression and disturbs cell cycle progression through a
PTEN-mediated inhibitory effect on the PI3K/Akt signaling
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therapeutic agent for preventing MSC dysfunction under
hyperglycemic conditions [70]. Recently Krishore et al.
demonstrated that intramyocardial delivery of BM SCs into
infarcted diabetic db/db mice significantly down-regulates
profibrotic miRNA-155 in the myocardium and improves
LV remodeling and function. Furthermore, inhibition of
paracrine factor hepatocyte growth factor signaling in vivo
suppressed the BM stem cell-mediated inhibition of
miR-155 expression and the associated protective effect
on cardiac fibrosis and function. This study indicates that
paracrine regulation of cardiac miRNAs by transplanted
BM SCs contributes to the antifibrotic effects of BM stem
cell therapy. These data suggest that targeting miR-155
might serve as a potential therapy against cardiac fibrosis
in the diabetic heart [71].
Cardiac niche enhancement to rescue the cardiac homing
capacity of SCs
Zeng et al. investigated whether Angiotensin-1 (Ang-1)
affects CD133+/c-kit+ cell recruitment to the infarcted
myocardium thereby mediating cardiac repair in type
2 diabetic mice. Diabetic mice were administered either
adenovirus Ang-1 (Ad-Ang-1) or Ad-β-gal systemically
immediately after ligation of the left anterior descending
coronary artery. Overexpression of Ang-1 resulted in
a significant increase in CXCR-4/SDF-1α expression
and promoted CD133+/c-kit+, CD133+/CXCR4+ and
CD133+/SDF-1α+ cell recruitment into ischemic hearts.
Overexpression of Ang-1 led to significant increases
in number of CD31+ and smooth muscle-like cells and
VEGF expression in BM. This was accompanied by
significant decreases in cardiac apoptosis and fibrosis
and an increase in myocardial capillary density. Over-
expression of Ang-1 resulted in a significant improve-
ment of cardiac functional recovery after 14 days of
ischemia. These data strongly suggest that Ang-1
attenuates cardiac apoptosis and promotes cardiac repair
by a mechanism involving in promoting CD133+/c-kit+
cells and angiogenesis in diabetic mouse infarcted
hearts [72].
Conclusions
CVDs continue to be a major global cause of death
and are usually preceded by high morbidity and medical
cost. Advances in interventional cardiovascular medicine
such as catheter-based interventions and coronary artery
bypass surgery have remarkably improved cardiovascular
survival, but many patients with coronary artery disease
are not candidates to undergo repeated interventions
or surgical revascularization. Despite numerous preclinical
studies and some early clinical trial evidence that
myocardial perfusion and function improve following
treatment with exogenous growth factors, gene therapy orcellular therapies, clinical studies have found very modest
effects on clinical indicators and no clear benefit on
patient survival. Cardiac regeneration has been explored
for long time with a very promising hope; however,
it remains early in this emerging field. Although early
human pilot studies showed the positive results on
cardiac regeneration with intra-coronary injection of
BM SCs [73], the recently randomized and controlled
clinical trials using MSCs have shown very modest if
any positive results [74-76]. Although human CSCs
have been positively applied in small number of patients
with ischemia/reperfusion cardiomyopathy, its translation
and wider applicability remains an issue since in autologous
CSC–derived therapy, the time taken for cell culture could
mean that the window for optimal benefit may be missed
in patients with recent acute MI. If the efficacy of CSCs is
confirmed in larger phase II studies, this would represent a
paradigm shift in the management of patients with cardiac
dysfunction due to prior MI.
Diabetes remains an epidemic disease, and diabetes
further impairs the cardiac defensive capacity to prevent
or recover from injury, leading to the further susceptibility
to cardiac damage, pathologic remodeling, and dysfunction.
As discussed above, emerging evidence supports the
concept that a “cardiac SC compartment disease” plays an
important role in the pathophysiology of diabetic cardiomy-
opathy. In diabetes, hyperglycemia, hyperlipidemia, inflam-
mation, and the consequent oxidative stress are enhanced,
leading not only to reduction of CSCs in terms of number
and its proliferative capacity, but also to reduced BMC
survival, impaired differentiation capacity to CM, and
reduced cardiac repair and reverse remodeling. These
negative effects on the diabetic myocardial niche contribute
to an imbalance between cell death and survival and
contribute to the onset of diabetic cardiomyopathy and
its progression towards heart failure. The preservation
of CSC compartment or cardiac environments favoring to
homing of BM SCs into damaged heart could contribute
to counteract the negative impact of diabetes on the
myocardium.
Finally, the application of iPSC technologies to generate
autologous CM for cardiac repair and regeneration
has shown positive early results in the ability to improve
diabetes-induced cardiac cell death, oxidative damage,
remodeling along with the inhibition of new angiogenesis,
and cardiac dysfunction [60,61]. This field is rapidly
advancing towards human clinical trials and data on
the safety and efficacy of iPS-CM in the healthy and
diabetic myocardium should become available over
the next decade.
Therefore, we have believed that therapy with SCs
for diabetic cardiomyopathy may eventually become an
effective approach in clinical settings for the diabetic
patient at high risk for life-threatening CVD [77,78].
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